Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context

Patricia M. Danzon, Adrian K. Towse, Jorge Mestre-Ferrandiz

NBER Working Paper No. 18593
Issued in December 2012
NBER Program(s):Health Economics

This paper analyzes pharmaceutical pricing between and within countries to achieve second best static and dynamic efficiency. We distinguish countries with and without universal insurance, because insurance undermines patients' price sensitivity, potentially leading to prices above second-best efficient levels. In countries with universal insurance, if each payer unilaterally sets an incremental cost effectiveness ratio (ICER) threshold based on its citizens' willingness to pay for health; manufacturers price to that ICER threshold; and payers limit reimbursement to patients for whom a drug is cost-effective at that price and ICER, then the resulting price levels and use within each country and price differentials across countries are roughly consistent with second best static and dynamic efficiency. These value-based prices are expected to differ cross-nationally with per capita income and be broadly consistent with Ramsey Optimal Prices. Countries without comprehensive insurance avoid its distorting effects on prices but also lack financial protection and affordability for the poor. Conditions for efficient pricing in these self-pay countries include that consumers are well-informed about product quality and firms can price discriminate between rich and poor subgroups within and between countries.

download in pdf format
   (155 K)

email paper

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w18593

Published: Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, 03. citation courtesy of

Users who downloaded this paper also downloaded* these:
Danzon, Mulcahy, and Towse w17174 Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
Danzon and Epstein w14041 Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
Danzon and Furukawa w17226 Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
Danzon and Keuffel Regulation of the Pharmaceutical-Biotechnology Industry
Danzon, Wang, and Wang w9874 The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us